StockData
Ocular Therapeutix, Inc logo

Ocular Therapeutix, Inc (OCUL) stock

OCULNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 9, 2026Score 3/3011% above fair value
$6.02+0.01 (+0.17%)

Close on Nov 17, 2026Market cap $1.32BP/E –Yield –

Ocular Therapeutix price to sales ratio

The price-to-sales ratio is market cap divided by revenue over the trailing twelve months.

Ocular Therapeutix's price to sales ratio was 28.1× on Nov 11, 2026, against 38.1× a year earlier. Over the last 5 years it ranged from 3.4× to 44.3×, with a median of 17.9×.

Price to Sales Ratio at the end of each year

PeriodPeriod endValueChange (pts)
2026Nov 11, 202628.1×−10.0
2025Dec 31, 202538.1×+16.3
2024Dec 31, 202421.8×+15.6
2023Dec 29, 20236.1×+1.8
2022Dec 30, 20224.4×−9.5
2021Dec 31, 202113.8×−92.2
2020Dec 31, 2020106.1×+29.3
2019Dec 31, 201976.7×−5.0
2018Dec 31, 201881.7×+14.6
2017Dec 29, 201767.2×−47.8
2016Dec 30, 2016114.9×−12.5
2015Dec 31, 2015127.4×–

More Ocular Therapeutix figures

See a number that looks wrong?